EUCTR2005-002772-14-DE进行中（未招募）不适用
A 13-week, multicenter, randomized, double-blind, double-dummy,placebo-controlled, parallel group trial oflumiracoxib (COX189) 100 mg o.d. in patients with primaryhip osteoarthritis using celecoxib (200 mg o.d.) as apositive control
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •At screening (Visit 1):
- •1. Male or female outpatients 40 years of age or older
- •2. Who have the highest pain intensity occurring in the target hip joint, relative to other OA joints (including the contralateral hip).
- •3. With a diagnosis of primary hip osteoarthritis which meets ACR criteria and have symptoms present for at least 3 months prior to screening. Diagnosis can be made at screening if symptoms have been present for 3 months by history.
- •4. Who have taken NSAIDs or simple analgesic therapy at least 50% of the time in the previous month (i.e. for 15 or more days (either successive or not) in the past 30 days) and who in the opinion of the investigator will require NSAID therapy for at least 13 weeks.
- •5. Who have sedentary pain (pain while sitting or lying down) for at least 2 days of the week and non-sedentary pain for at least 50% of the days in the previous month (i.e. for 15 or more days (either successive or not) in the past 30 days).
- •6. And who present at Baseline (Visit 2) with an:
- •OA pain intensity of at least 40 mm (0-100 mm VAS) in the target hip during the last 24 hours, and an increase in OA pain intensity since the screening visit of >= 20% and >= 10mm. Those patients who reach 100 mm before achieving a 20% increase will still be eligible as long as the increase is at least 10 mm.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Who have OA pain intensity of the knee(s) >= 30 mm (0-100 mm VAS) at screening.
- •2. With symptomatic osteoarthritis of the contralateral hip or spine that may, in the investigator's opinion, interfere with assessment of the target hip joint.
- •3. With secondary osteoarthritis with history and/or any evidence in the potential target joint of the following diseases: septic arthritis, gout, recurrent episodes of pseudogout, Paget's disease of bone, articular fracture, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary osteochondromatosis, heritable disorders (e.g. hypermobility), or collagen gene mutations
- •4. With primary fibromyalgia (secondary fibromyalgia is allowed if, in the opinion of the investigator it will not interfere with the patient's OA pain assessment)
- •5. Who had open knee/hip surgery within the last year, or observational arthroscopy, arthroscopic surgery or lavage within the last 180 days (in the knee or hip).
- •6. Who expect, or in the opinion of the investigator are expected, to have replacement of the target joint within 4 months of enrollment
- •7. With rheumatoid arthritis, systemic lupus erythematosus, or other inflammatory joint disease
- •8. With adult juvenile chronic arthritis (juvenile chronic arthritis with continued activity in adulthood)
- •9. With sarcoidosis
- •10. With symptomatic (source of hip pain) trochanteric bursitis of the target joint
- •11. With complete, even if focal, loss of articular cartilage on weight-bearing X-ray of the target joint
研究者
相似试验
进行中（未招募）
不适用
A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of lumiracoxib COX189 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib 200 mg o.d. as a positive controlMedDRA version: 6.1Level: PTClassification code 10024776OsteoarthritisEUCTR2005-002772-14-ITOVARTIS FARMA1,200
进行中（未招募）
1 期
A 13-week, multicenter, randomized, double-blind, doubledummy, placebo-controlled, parallel group trial of lumiracoxib (COX189) 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib (200 mg o.d.) as a positive controlPrimary osteoarthritis of the hipMedDRA version: 8.0 Level: LLT Classification code 10020108EUCTR2005-002772-14-GBovartis Pharma Services AG
未知
3 期
Double-blind study of treatment with LCZ696 in asian elderly patients with essential hypertensioEssential HypertensionJPRN-jRCT2080221938ovartis Pharma K.K.576
招募中
不适用
Effect of bamboo shavings (Phyllostachyos Caulis in Taeniam) extract on improvement of height growthKCT0001714Korea Medicine Research Institute60
已完成
不适用
Human body test for evaluating the efficacy and safety of white ginseng extract for liver functioSymptoms, signs and abnormal clinical and laboratory findings, NECKCT0004080International Ginseng & Herb Research Institute60